These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3342281)

  • 21. About 8-methoxypsoralen: difference in the efficiency of two delivery forms.
    van Hofwegen PM; Winkelman A
    Dermatologica; 1979; 158(4):307. PubMed ID: 428617
    [No Abstract]   [Full Text] [Related]  

  • 22. Improving the oral bioavailability of sulpiride by sodium oleate in rabbits.
    Naasani I; Kohri N; Iseki K; Miyazaki K
    J Pharm Pharmacol; 1995 Jun; 47(6):469-73. PubMed ID: 7674129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of three formulations of diphenylhydantoin in the dog.
    Overduin LM; van Gogh H; Mol JA; van Nes JJ
    Res Vet Sci; 1989 Mar; 46(2):271-3. PubMed ID: 2704892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stable bioavailability of cyclosporin A, regardless of food intake, from soft gelatin capsules containing a new self-nanoemulsifying formulation.
    Yang SG; Kim DD; Chung SJ; Shim CK
    Int J Clin Pharmacol Ther; 2006 May; 44(5):233-9. PubMed ID: 16724578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioavailability of flufenamic acid in hard and soft gelatin capsules.
    Angelucci L; Petrangeli B; Celletti P; Favilli S
    J Pharm Sci; 1976 Mar; 65(3):455-6. PubMed ID: 1263104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey.
    Perlin E; Smith CG; Nichols AI; Almirez R; Flora KP; Cradock JC; Peck CC
    J Pharm Sci; 1985 Feb; 74(2):171-4. PubMed ID: 2985774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An improvement in digoxin bioavailability. Studies with soft gelatin capsules containing a solution of digoxin.
    Alvisi V; Longhini C; Bagni B; Portaluppi F; Ruina M; Fersini C
    Arzneimittelforschung; 1979; 29(7):1047-50. PubMed ID: 582997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinetics of 8-methoxypsoralen and 5-methoxypsoralen distribution in guinea pig serum, epidermis and ocular lens.
    Wamer W; Giles A; Kornhauser A
    Photodermatol; 1987 Oct; 4(5):236-9. PubMed ID: 3697346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of formulation on the pharmacokinetics and bioavailability of racemic ketoprofen in horses.
    Landoni MF; Lees P
    J Vet Pharmacol Ther; 1995 Dec; 18(6):446-50. PubMed ID: 8789698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical study of a new preparation of 8-methoxypsoralen in photochemotherapy.
    el-Mofty AM; el-Sawalhy H; el-Mofty M
    Int J Dermatol; 1994 Aug; 33(8):588-92. PubMed ID: 7960360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture.
    Joshi HN; Tejwani RW; Davidovich M; Sahasrabudhe VP; Jemal M; Bathala MS; Varia SA; Serajuddin AT
    Int J Pharm; 2004 Jan; 269(1):251-8. PubMed ID: 14698596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the bioavailability and pharmacokinetics of two extended-release theophylline formulations in dogs.
    Bach JE; Kukanich B; Papich MG; McKiernan BC
    J Am Vet Med Assoc; 2004 Apr; 224(7):1113-9. PubMed ID: 15074856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound.
    Charman SA; Charman WN; Rogge MC; Wilson TD; Dutko FJ; Pouton CW
    Pharm Res; 1992 Jan; 9(1):87-93. PubMed ID: 1589415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The preparation and evaluation of a tablet dosage form of cyclosporine in dogs.
    Abdallah HY; Mayersohn M
    Pharm Res; 1991 Apr; 8(4):518-22. PubMed ID: 1871050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Difference in bioavailability between two brands of 8-methoxypsoralen and its impact on the clinical response in psoriatic patients.
    Herfst MJ; De Wolff FA
    Br J Clin Pharmacol; 1982 Apr; 13(4):519-22. PubMed ID: 7066167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator-Formulated Itraconazole Capsules and Solution in Healthy Dogs.
    Hasbach AE; Langlois DK; Rosser EJ; Papich MG
    J Vet Intern Med; 2017 Jul; 31(4):1163-1169. PubMed ID: 28627123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Problems with commercial formulations of 8-methoxypsoralen.
    Monbaliu JG; Bogaert MG; De Bersaques J; Hindryckx P
    Dermatologica; 1981; 163(6):468-73. PubMed ID: 7333402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time course of 8-methoxypsoralen concentrations in skin and plasma after topical (bath and cream) and oral administration of 8-methoxypsoralen.
    Tegeder I; Bräutigam L; Podda M; Meier S; Kaufmann R; Geisslinger G; Grundmann-Kollmann M
    Clin Pharmacol Ther; 2002 Mar; 71(3):153-61. PubMed ID: 11907489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of methoxsalen dose on ultraviolet-A-induced erythema.
    Ibbotson SH; Dawe RS; Farr PM
    J Invest Dermatol; 2001 May; 116(5):813-5. PubMed ID: 11348476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parenteral administration of 8-methoxypsoralen.
    Knobler RM; Trautinger F
    Br J Clin Pharmacol; 1996 Sep; 42(3):404. PubMed ID: 8877036
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.